PT-141 (Bremelanotide)
WellnessAlso known as: Bremelanotide, Vyleesi
Well-StudiedWhat is PT-141 (Bremelanotide)?
The only FDA-approved peptide for hypoactive sexual desire disorder (HSDD) in premenopausal women, marketed as Vyleesi. Unlike other sexual dysfunction treatments, it works through the nervous system rather than the vascular system.
How it works
Activates melanocortin receptors (MC3R and MC4R) in the central nervous system, modulating neural pathways involved in sexual arousal and desire. This is a fundamentally different mechanism from PDE5 inhibitors like sildenafil, which act on blood flow.
What marketers claim
- ▸works for everyone regardless of cause
- ▸instant aphrodisiac effect
- ▸no side effects
- ▸cures all sexual dysfunction
What evidence supports
- ✓FDA-approved (as Vyleesi) for HSDD in premenopausal women based on phase III trials
- ✓statistically significant increase in sexual desire scores vs placebo in clinical trials
- ✓novel mechanism of action through melanocortin pathway, distinct from vascular-based treatments
Best for
Safety notes & concerns
Full safety guide →- ⚠FDA approval is specifically for HSDD in premenopausal women — off-label use is not well-studied
- ⚠common side effects include nausea (40% of users), flushing, and headache
- ⚠can cause transient increases in blood pressure
- ⚠may cause skin hyperpigmentation with repeated use
- ⚠not to be used more than once in 24 hours or more than 8 times per month per labeling
- ⚠compounded versions are unregulated and may differ from the approved formulation
Pairs well with
Use caution with
Frequently asked questions
Is PT-141 the same as Vyleesi?
Yes. Vyleesi is the brand name for bremelanotide (PT-141), FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Compounded PT-141 from peptide suppliers contains the same molecule but is not subject to the same manufacturing and purity standards.
Does PT-141 work for men?
PT-141 is not FDA approved for use in men. Some early studies explored its use for erectile dysfunction, but development for that indication was discontinued. Off-label male use lacks robust clinical evidence and should only be considered under physician supervision.
Related wellness peptides
those interested in experimental recovery support with medical supervision
skin hydration support, joint comfort, general wellness
clinically obese patients under physician supervision, type 2 diabetes management
those following longevity research who pursue protocols with medical supervision
Take the Peptide Quiz
Get personalized recommendations
Stack Builder
Build a routine with PT-141 (Bremelanotide)
Last updated: 2025-03-21
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.